Clinical Trials

Inclusion Criteria:

• Subjects between ages of 18-75 years old.
• Newly initiated Mayo Clinic HPN patient.
• Able to provide informed consent.
• Anticipated duration of HPN greater than 3 months.
• Infusion company is able to provide Smoflipid.

Exclusion Criteria:

• Age < 18 years.
• Pregnant and lactating women.
• Failure to provide consent.
• Patients with underlying liver dysfunction (defined as liver function studies ≥ 2 times upper limit of normal) or pathology as determined by primary investigator.
• Patients with active malignancy.
• Patients who are deemed to be on HPN for less than three months.
• Patients who have previous proven addiction and dependence to alcohol/ heavy alcohol AND consumption/active use reported during last 12 months.
• Known hypersensitivity to fish, egg, soybean, or peanut protein, or to any of the active ingredients or excipients in Smoflipid.
• Patients who will not be managed by the Mayo Clinic HPN team.
• Patients who have active infection (as determined by the clinician) at the time of enrollment.
• Patients who have received Smoflipid greater than 4 weeks in the last 12 months prior to enrollment.
• Patients who have been on TPN greater than 4 weeks in the last 12 months prior to enrollment.
• Enrolled in another interventional study.
• Severe hyperlipidemia or severe disorders of lipid metabolism with serum triglycerides > 1,000 mg/dL.